Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Jul 1, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new imaging technique called FAPi PET/CT to see how it can help identify and understand different types of cancer in patients. The study looks at how a special tracer (68Ga-FAPi-46) gathers in cancer tissues and normal tissues. By using this imaging method, researchers hope to gain more insights into various cancers, which may help improve diagnosis and treatment in the future.
To participate in this study, patients must be at least 18 years old and diagnosed with specific types of cancer, such as brain, bladder, skin, thyroid, and several others. They should also be scheduled for surgery or a tissue biopsy. Participants will undergo an imaging procedure that lasts about an hour, where they will need to stay still. It's important to note that pregnant or nursing individuals cannot take part, and those undergoing new cancer treatments right before the imaging are also excluded. Overall, this study aims to gather valuable information that could shape how we understand and treat cancer moving forward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with the following cancer types:
- • Brain cancer
- • Bladder cancer
- • Urothelial cancer
- • Testicular cancer
- • Skin cancer
- • Thyroid cancer
- • Hepatocellular carcinoma
- • Cholangiocarcinoma
- • Thymus cancer
- • Pleural cancer
- • Cervical cancer
- • Adrenal cancer
- • Neuroendocrine tumors
- • Hematologic cancer
- • Cancer of Unkown Primary
- • Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
- • Patients are ≥ 18 years old at the time of the radiotracer administration.
- • Patient can provide written informed consent
- • Patient is able to remain still for duration of imaging procedure (up to one hour)
- Exclusion Criteria:
- • Patient is pregnant or nursing
- • Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
- • Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Jeremie Calais
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials